StocksMedium•13 November 2026•
1 min read
Allarity Therapeutics Ends Q3 with $24.1M Cash, Forecasts Q4 Profit
Key Facts
1Allarity Therapeutics ended the third quarter with $24.1 million in cash and restricted cash.
2The company expects positive fourth quarter earnings between $0.01 and $0.04 per share.
Allarity Therapeutics ended the third quarter of 2026 with $24.1 million in cash and restricted cash. GlobeNewswire reported that the company expects to achieve positive fourth-quarter earnings ranging between $0.01 and $0.04 per share, according to its latest financial results and full-year guidance.
ALLR closed at $0.9138 on November 12, 2026, having reached a day high of $0.9722 and a low of $0.8801. These financial updates follow the company's continued focus on clinical and business activities after stabilizing its cash position at the end of September 2026.